Bruker AXS Announces Novel Protein Crystal Screening System; High-Throughput Screening Prior to Structure Determination Increases Efficiency.

ORLANDO, Fla. -- Bruker AXS Inc. today announces the launch of a new system for high-throughput protein crystal screening at the 2005 American Crystallographic Association meeting in Orlando. The new X8 PROSPECTOR(TM) allows protein crystals to be rapidly screened with X-rays to determine their diffraction quality prior to X-ray structure determination in the home lab or at a synchrotron beamline.

The X8 PROSPECTOR combines a highly reliable, low maintenance X-ray source with advanced multi-layer optics and a fast, ultra-sensitive CCD detector to provide exceptional ease-of-use and speed. Moreover, the X8 PROSPECTOR features X-ray source intensity comparable to conventional 5.4 kW rotating anode sources with total reflection optics, yet with much reduced cost of ownership. With the X8 PROSPECTOR, crystallographers can rapidly determine the diffraction limit, mosaicity and space group of even extremely small protein crystals, typically in less than 5 minutes per sample.

Though the X8 PROSPECTOR is primarily targeted towards crystal screening it features flexible, user-friendly software which allows it also to be used for other applications, such as absolute configuration of light-atom molecules and protein structure determination.

Dr. Roger Durst, Chief Technology Officer for Bruker AXS, stated: "The X8 PROSPECTOR is a powerful, high-throughput screening system with much lower operating and maintenance costs than conventional rotating anode-based systems. It allows users to find the highest quality crystals rapidly and cost-effectively for later analysis at a synchrotron beamline. This ensures that valuable beamline time is not wasted on lower quality samples."

About Bruker Biosciences (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com

Any statements contained in this press release with respect to Bruker AXS or Bruker BioSciences or their businesses that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.